RT11-i

**RT11-i** is an engineered human IgG1 monoclonal antibody designed to penetrate tumor cells and selectively bind the GTP-bound active form of oncogenic Ras mutants (KRas, NRas, HRas with G12, G13, or Q61 mutations), blocking their protein-protein interactions (PPIs) with effector proteins such as Raf, RalGDS, and PI3K at the switch I/II regions. This inhibits downstream signaling pathways including Raf-MEK-ERK and PI3K-Akt-mTOR, leading to suppressed tumor cell proliferation, reduced anchorage-independent growth, and induction of apoptosis specifically in Ras-mutant cells. Developed by researchers at Ajou University and Orum Therapeutics, it includes an N-terminal RGD10 peptide fusion for tumor-targeted delivery via integrin αvβ3/αvβ5 binding, enhancing tissue accumulation and in vivo efficacy in xenograft models of colorectal, pancreatic, lung, and fibrosarcoma tumors without significant toxicity to wild-type Ras tumors. It synergizes with gemcitabine and cetuximab to overcome resistance in KRAS-mutant pancreatic and colorectal cancers.[1][2][3][5][7][10]

Other names

iMabpan-RAS iMab